SESSION I: CAR-T, update clinical trials and RWE
P. Corradini
HG-BCL
S.J. SchusterFollicular lymphoma
C.A. JacobsonMantle cell lymphoma
J. MunozSESSION II: Hodgkin’s lymphoma
S.M. Ansell, P.L. Zinzani
1st relapse
S.M. AnsellNew agents in R/R patients
A.S. La CasceTreatment strategies in elderly patients
A. SuredaPrimary mediastinal lymphoma
K. DunleavyGrey zone lymphoma
S.M. AnsellLectures on PROTAC therapies
B.D. Cheson
NX-2127
A.V. DanilovBGB-16673
C. CheahSESSION III: Acute leukemias
A. Curti, A. Venditti
Targeting CD123 in AML and BPDCN
P. MinettoAnti-CD47 MoAbs in AML and MDS
D.A. SallmanImmune checkpoint inhibitors in AML and MDS
G. Garcia-ManeroT-cell engagers in AML and ALL
M. SubkleweIDH inhibitor: ivo, ena and beyond
S. De BottonBCL2 inhibitors: not only venetoclax
A.H. WeiNovel FLT3 inhibitors
M. LevisSubcutaneous blinatumomab in adult ALL
A. RambaldiMenin-inhibitors
C. PapayannidisTargeting the BCL2/BCLx pathway in T-ALL
E.J. JabbourCAR-T cells for adult ALL and AML
M. RuellaSESSION IV: Classical Ph1-neg myeloproliferative neoplasms
F. Palandri, A.M. Vannucchi
Cytoreduction in low-risk PV: when, and which drug?
H. GisslingerThe future of 1st line therapy in myelofibrosis
A. KuykendallSecond-line therapy of myelofibrosis
H.K. Al-AliMPNs in accelerated/blast phase
P. GuglielmelliSESSION V: Non-Hodgkin’s lymphoma (I)
C. Carlo-Stella, M. Ladetto
Tafasitamab
J.A. DuellEpcoritamab
C. ThieblemontGlofitamab
M. DickinsonMosunetuzumab
E.L. BuddeOdronextamab
W.S. KimTNB-486
R.W. JacobsPolatuzumab vedotin
B.D. ChesonLoncastuximab tesirine
M. HamadaniTazemetostat
J.M. MichotSESSION VI: Non-Hodgkin’s lymphoma (II)
M. Martelli, M. Spina
Zilovertamab
P.M. BarrLinperlisib
S.P. IyerPirtobrutinib
W. JurczakGolidocitinib
W.S. KimValemetostat
S.M. HorwitzIberdomide
C. ThieblemontGolcadomide
J.M. MichotCDK9 inhibitors
J. ZainSESSION VII: Non-Hodgkin’s lymphoma - The next steps of CAR-T
S.J. Schuster
New generations of CAR-T
S.J. SchusterAllo CAR-T
S.S. NeelapuCAR-NK cells
K. RezvaniGamma delta CART19
S.S. NeelapuSESSION VIII: Chronic myeloid leukemia
M. Breccia, F. Castagnetti
Status of the art of treatment
M. BrecciaAsciminib
D. ReaPonatinib
F. CastagnettiSecond generation TKIs
T.H. BruemmendorfNew agents
M. BonifacioLecture
N. Vianelli
SESSION IX: Chronic lymphocitic leukemia
W. Jurczak, A. Tedeschi
Ibrutinib
W. JurczakVenetoclax
O. Al-SawafAcalabrutinib
J.C. ByrdZanubrutinib
J. BrownPirtobrutinib
W. JurczakNemtabrutinib
J.C. ByrdBGB-11417
C. CheahCAR-T
T. SiddiqiSESSION X: Multiple myeloma
M. Cavo